Novo Nordisk A/S
NYSENovo Nordisk heads into its August 5 earnings report with short sellers adding positions at their fastest monthly pace in recent memory, even as the borrow market remains wide open. Short interest has climbed 30% over the past month, reaching roughly 31 million shares as of July 30. That build accelerated sharply in the week of July 21, when estimated short shares jumped from around…
NVO cost to borrow surges 111% in one week to 0.47%, though availability remains abundant at 1,364% of short interest.
A new long-form analysis for NVO this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumNovo Nordisk heads into its August 5 earnings report with short sellers adding positions at their fastest monthly pace in recent memory, even as the borrow market remains wide open. Short interest has climbed 30% over…
Snapshot as of 7 Aug 2026
Three converging signals on NVO are pointing in the same direction. Short sellers are unwinding positions at pace. Borrowing costs have collapsed. Options traders just flipped to their most bullish stance in a…
Novo Nordisk heads into its May 6 Q1 results on the back of a sharp recovery — and with the Street still broadly skeptical about what comes next. The stock has climbed 20% over the past month to $43.88, clawing back a…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NVO — free to start on ORTEX.
Sign up for free →Open NVO on ORTEX